LITT for Ultra-early GBM Recurrence

Summary

Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT/CT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy. LITT offers a minimally invasive alternative that may: * Treat recurrence without delaying RT/CT * Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.

Eligibility

Inclusion Criteria:

* Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status
* ≥18 years of age
* CRET
* Karnofsky Performance Status (KPS) ≥70
* No contra-indication for radio-chemotherapy
* Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern
* Able to provide informed consent
* No contra-indication for LITT
* No pregnancy or active breast-feeding
* No known coagulopathy independent of medication
* No dissemination or multifocal disease
* Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.

Exclusion Criteria:

Conditions3

Browse More Trials